Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CED with ACNU plus temozolomide for recurrent malignant spinal cord astrocytoma
jRCTs021180010Recruiting
- Start
- Aug 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of nimustine and temozolomide in spinal cord astrocytoma and glioma. Primary endpoint: Maximum tolerable concentration. Started Aug 2012; status: recruiting.
02
Drugs
nimustinetemozolomide
03
Conditions
spinal cord astrocytomaglioma
Beyond the preview
Go deeper on jRCTs021180010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180010.